PF-Atlas › Clinical Trials › NCT05153317

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 2 Years and Older

ELX/TEZ/IVA · Phase 3

Registry ID
NCT05153317
Phase
Phase 3
Status
Completed
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2022-01-17
Enrollment
71
Locations
22

About this trial

The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.

View NCT05153317 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761ELX/TEZ/IVA — NCT04105972
Medical disclaimer. This page summarizes public trial data for NCT05153317 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.